Supernus Pharmaceuticals

SUPN

Market cap $2.98B

Aristotle Capital Boston sold 503,122 shares of Supernus Pharmaceuticals in the third quarter. The move contributed to a net position change of about $10.9 million from the previous quarter.

Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will present at the Bank of America Securities 2025 CNS Therapeutics Virtual Conference on Monday, December 8, 2025, at 3:20 p.m. ET.

ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025, at 4:00 p.m. ET at the Lotte New York Palace in New York City.

ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.

Supernus Pharmaceuticals, Inc. ( SUPN ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Jack Khattar - Founder, President, CEO, Secretary & Director Timothy Dec - Senior VP & CFO Conference Call Participants Peter Vozzo - Westwicke Partners, LLC Lin Tsai - Jefferies LLC, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division David Amsellem - Piper Sandler & Co., Research Division Pavan Patel - BofA Securities, Research Division Stacy Ku - TD Cowen, Research Division Presentation Operator " Jack Khattar Founder, President, CEO, Secretary & Director " Timothy Dec Senior VP & CFO " Peter Vozzo Westwicke Partners, LLC " Lin Tsai Jefferies LLC, Research Division " Jefferies LLC, Research Division Annabel Samimy Stifel, Nicolaus & Company, Incorporated, Research Division " Stifel, Nicolaus & Company, Incorporated, Research Division David Amsellem Piper Sandler & Co., Research Division " Piper Sandler & Co., Research Division Pavan Patel BofA Securities, Research Division " BofA Securities, Research Division Stacy Ku TD Cowen, Research Division " TD Cowen, Research Division Operator Good afternoon, and welcome to the Supernus Pharmaceuticals Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $1.01 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $1.06 per share a year ago.

ROCKVILLE, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2025 and associated Company developments.

Does Supernus Pharmaceuticals (SUPN) have what it takes to be a top stock pick for momentum investors? Let's find out.